BioAge Labs announces multi-year collaboration with Novartis

BioAge Labs (BIOA) announced a multi-year research collaboration with Novartis (NVS). The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate the beneficial effects of physical exercise. “Our platform, built on extensive longitudinal human longevity data, has allowed us to identify promising therapeutic pathways with significant potential to improve health outcomes,” said Kristen Fortney, CEO and co-founder of BioAge. “This collaboration with Novartis showcases the value of our platform and expands our capacity to discover and develop novel targets based on the insights from our data.”